Clinical Trial Update: Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD) [Phase 2]

View source ↗

Summary

Phase 2 trial completed evaluating SNF472 for progression of vascular calcification in end-stage renal disease patients on hemodialysis; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Abnormalities
• Cardiovascular Diseases
• Coronary Artery Calcification
• End-stage Renal Disease
• Vascular Calcification

Drugs mentioned

• SNF472 (SNF472)

Snippet

Sponsor: Sanifit Therapeutics S. A. | Conditions: Cardiovascular Diseases, Cardiovascular Abnormalities | Phase 2 | Status: COMPLETED | Results posted: 2021-03-16